122TiP Phase III study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG 3515)
| Autor: | Robinson, C., Xing, L., Tanaka, H., Tasaka, S., Badiyan, S.N., Nasrallah, H., Biswas, T., Shtivelband, M., Schuette, W., Shi, A., Hepner, A., Barrett, K., Rigas, J.R., Jiang, H., Lin, S.H. |
|---|---|
| Zdroj: | In Annals of Oncology April 2022 33 Supplement 2:S88-S88 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|